Minang P. Turakhia
Chief Medical & Scientific Officer and Executive VP of Advanced TechnologiesDr. Minang P. Turakhia, M. D., M. S., M. A.S., also known as Mintu, serves as Chief Medical Officer and Chief Scientific Officer of iRhythm Holdings, Inc. (formerly known as iRhythm Technologies, Inc.) since April 28, 2022 and also served as its Executive Vice President of Product Innovation since April 2023 until August 2025 and serves as its Executive Vice President of dvanced Technologies since August 2025. He joined the executive leadership team to drive continued innovation, lead research and evidence generation and enhance and augment the portfolio of clinical products and services. He served as Member of Advisory Board at iRhythm Holdings, Inc. (formerly known as iRhythm Technologies, Inc.) until 2020. Dr. Turakhia is an internationally recognized cardiac electrophysiologist and leader in digital health and heart rhythm care. He has experience in patient care, outcomes research and trials, data science and artificial intelligence, medical device regulation and the creation and commercialization of digital health products. From August 2008 to June 2022, Dr. Turakhia served as Chief, Cardiac Electrophysiology at VA Palo Alto Health Care System, where he still practices and performs catheter ablation and device implantation. In 2014, Dr. Turakhia performed the first-ever study of silent atrial fibrillation with the original Zio patch1, which helped to propel the field to perform large atrial fibrillation studies at scale, including the iRhythm mSToPS Clinical Trial2. Dr. Turakhia is also a seasoned operator who has led the development of virtual care and remote patient monitoring software for clinical trials, academic research and commercialized health care products. Dr. Turakhia is a cardiac electrophysiologist, outcomes researcher and clinical trialist. He served as Member of Clinical Board at BrightInsight, Inc until 2022. Dr. Turakhia has an active, highly-funded multidisciplinary program in atrial fibrillation, where uses large datasets to examine quality, outcomes and risk prediction for heart rhythm disorders. As the Executive Director of Stanford’s new Center for Digital Health, he is the Principal investigator of several multi-center trials to test digital health tools and wearable devices to screen and manage heart rhythm disorders. He has served as Professor of Medicine (on leave) at the Stanford University School of Medicine since August 2008 and Director and Co-Founder of the Stanford Center for Digital Health. Dr. Turakhia is internationally recognized for his clinical, scientific and health technology work. He leads a large multidisciplinary research program in heart rhythm disorders, real-world evidence, clinical trials and digital health. He has led several large-scale trials of digital health tools and wearables for heart disease, including as co-Principal investigator of the landmark Apple Heart Study, enrolling over 400,000 participants and published in the New England Journal of Medicine. At the Center for Digital Health, he leads multiple large public-private Partnership efforts and led the creation of the American Heart Association-funded Stanford Heart Health Technology Center, where he created one of the first ever health technology fellowship training programs. In academic and industry roles, he has led teams to build and commercialize software-enabled disease management and remote patient monitoring programs for heart disease. In his clinical role as Director of Cardiac Electrophysiology at the VA, Palo Alto Health Care System and performs invasive procedures such as catheter ablation and device implantation to treat heart rhythm disorders. Dr. Turakhia performed invasive procedures such as catheter ablation and device implantation to treat heart rhythm disorders. Dr. Turakhia is a Fellow of the American Heart Association, American College of Cardiology and Heart Rhythm Society. He also holds a M.S. in Clinical Research from University of California, San Francisco and received clinical training at Harvard’s Brigham & Women’s Hospital the University of California, San Francisco. Dr. Turakhia holds a B.S. in Molecular Biology and Computer Science from the University of California, Berkeley and received his M.D. from the University of California, San Francisco.
Positions
- Company NameiRhythm Holdings, Inc.Stock CodeIRTCPositionChief Medical & Scientific Officer and Executive VP of Advanced TechnologiesColleagues
- QSQuentin S. BlackfordPresident, CEO & Director
- AYAbhijit Y. TalwalkarIndependent Chairman
- DGDaniel G. WilsonCFO & Principal Financial Officer
- PMPatrick Michael MurphyChief Business & Legal Officer
- CMChad M. PattersonChief Commercial and Product Officer
- BGBruce George BodakenIndependent Director
- KLKaren L. LingIndependent Director
- KKKaren K. McGinnisIndependent Director
